Revolution Medicines's top three insider shareholders as of August 04, 2026 are Rock Ventures Iii, L.P. Third (TenPercentOwner, 5.10Mn shares), Alexis Borisy (Director, 2.34Mn shares), Stephen Michael Kelsey (Officer, 295.40K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Mark A Goldsmith | - | 276,698 | 0 | 17 Apr, 2026 |
| Margaret A Horn | Chief Operating Officer | 157,570 | 0 | 19 Mar, 2026 |
| Alexis Borisy | - | 2,338,884 | 0 | 30 Jun, 2025 |
| Stephen Michael Kelsey | - | 295,398 | 0 | 19 Mar, 2026 |
| Rock Ventures Iii, L.P. Third | - | 5,104,130 | 0 | 10 Jun, 2022 |
| Neil Exter | - | 28,815 | 0 | 17 Jun, 2022 |
| Sandra Horning | - | 96,574 | 0 | 30 Jun, 2025 |
| Lorence H. Kim | - | 73,090 | 0 | 30 Jun, 2025 |
| Eric Thomas Schmidt | - | 21,251 | 0 | 12 Jun, 2023 |
| Elizabeth M Anderson | - | 8,215 | 15,000 | 06 Mar, 2026 |
| Frank Clyburn | - | 9,738 | 0 | 30 Jun, 2025 |
| Jack Anders | Chief Financial Officer | 125,512 | 0 | 19 Mar, 2026 |
| Barbara Weber | - | 13,065 | 0 | 10 Oct, 2024 |
| Xiaolin Wang | - | 116,063 | 0 | 19 Mar, 2026 |
| Sushil Patel | - | 23,090 | 0 | 30 Jun, 2025 |
| Flavia Borellini | - | 25,024 | 0 | 30 Jun, 2025 |
| Lin Wei | Chief Medical Officer | 101,366 | 0 | 19 Mar, 2026 |
| Jeff Cislini | General Counsel | 58,518 | 0 | 19 Mar, 2026 |
| Anthony Mancini | - | 54,400 | 0 | 26 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 15 Apr, 2026 | Mark A Goldsmith | Common Stock | A | 23,244 | $4.09 | 299,942 | D | M |
| 15 Apr, 2026 | Mark A Goldsmith | Common Stock | A | 96,756 | $4.73 | 396,698 | D | M |
| 15 Apr, 2026 | Mark A Goldsmith | Common Stock | D | 120,000 | $150.09 | 276,698 | D | S |
| 15 Apr, 2026 | Mark A Goldsmith | Stock Option (Right to Buy) | D | 23,244 | $0.00 | 24,464 | D | M |
| 15 Apr, 2026 | Mark A Goldsmith | Stock Option (Right to Buy) | D | 96,756 | $0.00 | 424,085 | D | M |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | A | 37,450 | $33.62 | 91,850 | D | M |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | D | 1,800 | $93.22 | 90,050 | D | S |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | D | 3,128 | $94.16 | 86,922 | D | S |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | D | 21,086 | $95.49 | 65,836 | D | S |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | D | 11,036 | $96.43 | 54,800 | D | S |
| 25 Mar, 2026 | Anthony Mancini | Common Stock | D | 400 | $97.21 | 54,400 | D | S |
| 25 Mar, 2026 | Anthony Mancini | Stock Option (Right to Buy) | D | 37,450 | $0.00 | 112,350 | D | M |
| 17 Mar, 2026 | Jeff Cislini | Common Stock | D | 1,795 | $99.48 | 59,681 | D | S |
| 17 Mar, 2026 | Lin Wei | Common Stock | D | 2,073 | $99.48 | 101,366 | D | S |
| 17 Mar, 2026 | Xiaolin Wang | Common Stock | D | 2,010 | $99.48 | 116,063 | D | S |
| 17 Mar, 2026 | Xiaolin Wang | Common Stock | D | 2,010 | $99.48 | 116,063 | D | S |
| 17 Mar, 2026 | Xiaolin Wang | Common Stock | D | 2,010 | $99.48 | 116,063 | D | S |
| 17 Mar, 2026 | Stephen Michael Kelsey | Common Stock | D | 4,302 | $99.48 | 295,398 | D | S |
| 17 Mar, 2026 | Lin Wei | Common Stock | D | 2,073 | $99.48 | 101,366 | D | S |
| 17 Mar, 2026 | Lin Wei | Common Stock | D | 2,073 | $99.48 | 101,366 | D | S |